Most myeloid cells have the phagocytotic ability to take up drug MPs and upon uptake, it can profoundly influence the biology of lysosomes, through which the phenotype and function of tumor‐infiltrating myeloid cells are altered, thus, remodeling TME MHC class II, IL‐12, and even IFN‐γ, suggesting that DCs are indeed activated by T‐MPs [22] (Fig. 1). The gene discussed is IFNG; the disease is neoplasm.